Search the Site

Twitter

test tubes

$RPTP Poised for Run-Up into January FDA Decision

publication date: Nov 26, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Written by Mike Havrilla--Raptor Pharma (RPTP) is a rare disease drug developer with a summary of the Company’s lead product candidate, PROCYSBI (RP103) (Cysteamine Bitartrate Delayed-Release Capsules), summarized below...


Sorry this page is available to subscribers only. If you're not a subscriber why not join today?

If you are already a subscriber, please login.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site including:

- Detailed Reports on Upcoming FDA and Clinical Trial Trades
- REAL TIME Posting of Trades (Entries and Exits)
- Clinical and Regualtory Catalyst Database with over 300 events and updated daily 
- Members Only Live Interactive Webinars 
- Live Chat Room 
- Video Lessons / Trade Reviews
- Chart / Technical Analysis 
- Run-Up Valuation Studies
- Weekly Watchlist Newsletter
- Email / SMS (Text Message) Alerts of critical news
- Access to view Mark Messier and Mike Havrilla's Trading Accounts
- A More Detailed FDA Calendar
- Historical FDA Tracker
- Bio-Pharma, FDA, Clinical Trials, and Stock Market News Updates
- Direct Email Communication
- Affiliate Program

If you believe you should be able to view this area then please contact us and we will try to rectify this issue as soon as possible.